BioNTech Axes 1,860 Jobs and Warns on Berlin's Health Agenda as Cancer Pipeline Takes Center Stage
04.06.2026 - 21:33:02 | boerse-global.de
BioNTech is swinging the axe deep into its own workforce while simultaneously firing a warning shot at the German government. The Mainz-based biotech plans to shutter four sites by the end of 2027, including its Marburg and Tübingen facilities, eliminating roughly 1,860 roles — nearly a quarter of all staff. The restructuring is expected to deliver annual cost savings of around €500 million, all of which will be redirected into oncology research.
The move comes as Eli Lilly also pulls back planned investments in Germany, and BioNTech has joined the US pharma giant in publicly criticising the federal government’s proposed healthcare reforms. The timing is sensitive. Founders U?ur ?ahin and Özlem Türeci are set to leave the company at year-end, handing a transformed business to new leadership.
Financial strain deepens
The numbers reveal why such drastic action is necessary. First-quarter 2026 revenue fell to €118.1 million, down from €182.8 million a year earlier, as Covid vaccine sales continue their rapid decline. The net loss widened to €532 million. For the full year, management sticks to a revenue forecast of €2.0 to €2.3 billion — enough to keep the lights on but far from the growth story that once drove the stock.
BioNTech is fighting back on multiple fronts. A share buyback programme of up to $1.0 billion, representing around 4.2% of outstanding shares, is running until May 2027. The company ended March with roughly €16.8 billion in cash, a war chest built during the pandemic that will fund the expensive pivot into cancer medicines.
Should investors sell immediately? Or is it worth buying BioNTech?
At €77.30 on Thursday, the stock managed a 1.44% gain for the day, but the weekly performance shows a 3.62% decline. Year-to-date, the shares have shed about 20%, and they trade more than 10% below their 200-day moving average.
ASCO data underwhelm the market
Against this backdrop of cost-cutting and political tension, BioNTech presented updated clinical data at the ASCO 2026 cancer conference. The spotlight fell on two key assets: Pumitamig and Gotistobart.
Pumitamig showed encouraging anti-tumour activity in first-line non-small cell lung cancer, supporting the ongoing registration-enabling part of the trial. Gotistobart delivered positive signals in heavily pretreated, platinum-resistant ovarian cancer, with durable anti-tumour activity, clinically relevant survival data, and a manageable safety profile.
Yet the market barely flinched. The stock dipped after the presentations, underlining a persistent disconnect: investors want commercial proof, not just clinical hope. The company is running more than 25 mid- to late-stage trials, including 13 registration-enabling programmes and several novel combinations. But the gap between promise and revenue remains wide.
Wall Street remains deeply split
Analyst opinions reflect the uncertainty. UBS upgraded BioNTech to Buy and lifted its price target to $135 from $117. David Dai at the Swiss bank highlights the underappreciated potential of the oncology pipeline. Jefferies also rates the stock a Buy with a $138 target.
Bernstein strikes a more cautious note, flagging concerns about the PD-L1/VEGF drug class to which Pumitamig belongs. Historical data suggest these drugs have struggled to demonstrate statistically clear survival benefits. Bernstein’s risk-adjusted peak pipeline sales estimate sits roughly 43% below consensus.
BioNTech at a turning point? This analysis reveals what investors need to know now.
Across 19 analyst targets, the average stands at $129.56, with a high of $158 and a low of $94 — a $64 spread that reflects how sharply the Street disagrees on the pipeline’s ultimate value.
The next milestones
BioNTech plans to file for approval of antibody drug BNT323 later this year. Multiple data readouts from late-stage trials are expected in the second half of 2026, which management hopes will clarify the path to regulatory approval and commercialisation.
The goal is to have ten cancer drugs on the market by the end of the decade. Whether the company can navigate the simultaneous pressures of a shrinking vaccine business, a costly restructuring, political headwinds at home, and the departure of its founders will determine whether that ambition becomes reality — or whether the stock remains stuck between analyst hopes and market scepticism.
Ad
BioNTech Stock: New Analysis - 4 June
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
